Rilpivirine injection, in combination with cabotegravir injection and tablets approved for use in the EU for the treatment of HIV

This combination is the first approved long acting injectable treatment for HIV, which can be taken without the requirement of taking daily oral tablets. Approval was based on the phase III ATLAS, FLAIR and ATLAS-2M studies.

Source:

PharmaTimes